A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Pexelizumab (Primary)
- Indications Coronary disorders; Myocardial infarction
- Focus Therapeutic Use
- Acronyms PRIMO-CABG-2; PRIMO-CABG-II
- Sponsors Alexion Pharmaceuticals
- 01 Jul 2011 Results published in the Journal of Thoracic and Cardiovascular Surgery.
- 24 Mar 2009 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History